Shimada, Yoshihisa
Yoshioka, Yusuke
Kudo, Yujin
Mimae, Takahiro
Miyata, Yoshihiro
Adachi, Hiroyuki
Ito, Hiroyuki
Okada, Morihito
Ohira, Tatsuo
Matsubayashi, Jun
Ochiya, Takahiro
Ikeda, Norihiko
Funding for this research was provided by:
a Grant-in-Aid for Cancer Research from the Ministry of Education, Culture, Sports and Technology (#18K08799)
Project for Cancer Research and Therapeutic Evolution (22ama221405h0001)
the Project for Cancer Research and Therapeutic Evolution (JP20cm0106402)
Article History
Received: 16 December 2022
Accepted: 21 March 2023
First Online: 24 March 2023
Competing interests
: Y. Shimada, Y. Yoshioka, Y. Kudo, T. Mimae, Y. Miyata, H. Adachi, H. Ito, M. Okada, T. Ohira, J. Matsubayashi, and T. Ochiya have no conflicts to disclose. N. Ikeda reports grants and personal fees from AstraZeneca, grants and personal fees from Boehringer Ingelheim, grants and personal fees from Chugai Pharma, grants and personal fees from Eli Lilly, grants and personal fees from MSD, grants and personal fees from Nihon Medi-Physics, grants and personal fees from Ono Pharmaceutical, grants and personal fees from Pfizer, grants and personal fees from Taiho Pharmaceutical, grants and personal fees from Teijin, and personal fees from Bristol-Meyers Squibb Japan outside the submitted work.